To receive all Acticor Biotech financial information in real time, request it by email to [email protected]
– Capital increase composed of an offer to qualified investors and an offer to individual investors via the PrimaryBid platform
– Subscription commitments from Mr. Rinaldo del Bono, founder of Mediolanum farmaceutici, and the Belgian company M3 for a total of €1.5 million
– Issue price of new shares of €3 per share
– Closing of the PrimaryBid Offer on November 27, 2023 at 10:00 p.m. and of the Global Placement on November 28, 2023 before the markets open
– The funds raised will be allocated to financing the continuation of the ACTISAVE study until the results expected in Q2 2024